



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

December 5, 2023: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**
- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)
- **DVHA Pharmacy Administration Updates** **6:35 - 6:50**
 - Gold Card Report
- **Chief Medical Officer Updates** **6:50 - 6:55**
- **Follow-up Items from Previous Meetings** **6:55 – 7:00**
 - Xeljanz® (tofacitinib) oral solution
 - Kesimpta® (ofatumumab)
- **RetroDUR/ProDUR** **7:00- 7:25**
 - Data presentation: *“Triple Therapy”: Opioids, Benzodiazepines, and Skeletal Muscle Relaxants*
- **Clinical Update: Drug Reviews** **7:25-7:45**
(Public comment prior to Board action)
- **Biosimilar Drug Reviews**
 - None at this time.
- **Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Abilify Asimtufii® (aripiprazole) and Uzedy® (risperidone)
 - Inpefa® (sotagliflozin)
 - Liqrev® (sildenafil)
 - Konvomep® (omeprazole and sodium bicarbonate)
 - Qalsody® (tofersen)
 - Rebyota™ (fecal microbiota, live- jslm) and Vowst™ (fecal microbiota spores, live-brpk)
 - Syfovre® (pegcetacoplan)
 - Veozah™ (fezolinetant)
 - Zavzpret™ (zavegepant)
- **New Managed Therapeutic Drug Classes** **7:45 -7:55**

- Ophthalmic, Anti-VEGF and Miscellaneous Agents (new drug Syfovre® (pegcetacoplan) included)
(Public comment prior to Board action)
 - None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:55 - 8:30**
(Public comment prior to Board action)
 - Gastrointestinal Ulcer Therapies (new drug Konvomep® (omeprazole and sodium bicarbonate) included)
 - H. Pylori Combination Treatments
 - Hyperuricemia and Gout
 - Ophthalmic, Allergic Conjunctivitis
 - Ophthalmic, Antibiotics
 - Ophthalmic, Anti-Inflammatories
 - Ophthalmic, Dry Eye Treatments
 - Ophthalmic, Glaucoma Agents
 - Platelet Aggregation Inhibitors

- **Review of Newly Developed/Revised Criteria** **8:30 - 8:30**
(Public comment prior to Board action)
 - None at this time.

- **General Announcements** **8:30 – 8:30**
 - None at this time.

- **Adjourn** **8:30**